MAVMET: Maraviroc ± Metformin for the Treatment of NAFLD in Virologically Suppressed Adults With HIV

October 27-30, 2021; London, United Kingdom
Maraviroc ± metformin, in addition to ART, was safe with acceptable tolerability but did not reduce liver fat percentage vs no adjunctive treatment.
Format: Microsoft PowerPoint (.ppt)
File Size: 164 KB
Released: November 3, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options (CCO) downloadable slides from Drs Joseph Eron, Karine Lacombe, Chloe Orkin, and Babafemi Taiwo on HIV data from IDWeek and HIV Glasgow 2022

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: November 22, 2022

Read an expert’s perspective on the management of patients with multidrug-resistant HIV with limited treatment options using new antiretroviral agents, from Clinical Care Options (CCO)

Josep M. Llibre, MD, PhD Released: November 17, 2022

Expert insights on key advances in HIV treatment from the past year, from Drs Joseph Eron, Monica Gandhi, Patrick Mallon, and Clinical Care Options (CCO)

Patient advocates and experts discuss barriers and calls to action regarding HIV treatment support and engagement, from Clinical Care Options (CCO)

Dázon Dixon Diallo, DHL, MPH
Program Director
Jason Halperin, MD, MPH Winnie Sseruma Marc Thompson
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: November 16, 2022 Expired: November 15, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings